BioMarin snaps up Alesta's lead asset for $275M
BioMarin will acquire Alesta's experimental therapy for rare bone disease hypophosphatasia for up to $490 million.
AstraZeneca’s volrustomig hits Phase 3 setback in lung cance...
In another blow to its late-stage pipeline, AstraZeneca has pulled the plug on a phase 3 trial of its lung cancer treatment volrustomig.
Sandoz adds 10 biosimilars through $322m Henlius deal
Sandoz is set to add up to 10 new biosimilar assets to its portfolio under a new collaboration deal with China’s Shanghai Henlius Biotech.
MHRA clarifies UK position on microbiome-based medicines
The MHRA has published its position paper clarifying how microbiome-based medicines can be made available for patients in the UK.
Australia first for Hansa’s Idefirix in commercial kidney tr...
Hansa has announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
The Pharmaceutical Launch Excellence Summit
Where pharma leaders share strategies for successful drug launches.
Inizio Launches Connected Insights to Transform Global Medic...
Expanded APAC expertise, enhanced global infrastructure, and AI-enabled innovation to help life sciences organizations
9th Lab Asset & Facility Management Summit
Enabling Leaner, Smarter & More Resilient R&D Labs
The Evolution Summit Announces September 2026 Program for Cl...
Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.
Register Now for AAPS PharmSci 360!
Learn from pharmaceutical scientists involved at every stage of the drug development pipeline at PharmSci 360.